MedTrace Logo

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

NCT04871035 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-05-01

No results posted yet for this study

Summary

This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.

Conditions

  • GBS

Interventions

DEVICE

Immunoadsorption

1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.

DEVICE

Plasma Exchange

1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.

Sponsors & Collaborators

  • DiaMed GmbH

    collaborator INDUSTRY

  • University of Ulm

    lead OTHER

Principal Investigators

  • Johannes Dorst, Prof · University of Ulm

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2027-09-01
Completion
2027-09-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871035 on ClinicalTrials.gov